BioSpace News Archive

Bloomage Biotech, a leader in sodium hyaluronate products, and Lumenis, a pioneering medical laser equipment provider, have collaboratively released the new M22 medical wound dressing for postoperative laser skin treatments care.

ObvioHealth and Mi-Helper, Inc. announce a partnership to conduct a decentralized clinical trial for a non-invasive neuromodulation device for the treatment of migraines.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that more than 10,000 people with amyotrophic lateral sclerosis (ALS) have received treatment with intravenous (IV) RADICAVA® (edaravone) and/or RADICAVA ORS® (edaravone) since the therapies became available in the U.S. in August 2017 and June 2022, respectively.

Radiance Therapeutics, Inc. is delighted to announce that its CEO, Laurence Marsteller, MSc. MD, will be representing the company at the LSI USA ’23 Emerging Medtech Summit, which will take place on March 20-23, 2023 in Dana Point, California.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark”) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that novel liquid biopsy data presented this week suggests that Pulmonary Neuroendocrine Tumors (NETs) are reprogramming their metabolism as reflected by the presence of a panel of distinct metabolic biomarkers

Event will feature industry leaders, cutting-edge technology in cell line development CAMBRIDGE-March 16, 2023- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, will host the Sartorius Summit:

Oculis Holding AG (Nasdaq: OCS) (“Oculis”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the completion of enrollment for its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2022 on Thursday, March 23, 2023.

Pfizer Inc. announced that the U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2022.